E-LIB Suche - Ergebnisse für: Csőszi, Tibor

1

A global phase II randomized trial comparing oral taxane Mo..:

Vaishampayan, Ulka N. ; Keessen, Marianne ; Dreicer, Robert...
European Journal of Cancer. 202 (2024) - p. 114007 , 2024

Link: https://doi.org/10.1016/..

2

Pembrolizumab With or Without Lenvatinib for First-Line Met..:

Yang, James Chih-Hsin ; Han, Baohui ; De La Mora Jiménez, Emmanuel...
Journal of Thoracic Oncology. 19 (2024) 6 - p. 941-953 , 2024

Link: https://doi.org/10.1016/..

3

Pembrolizumab with or Without Lenvatinib as First-line Ther..:

Matsubara, Nobuaki ; de Wit, Ronald ; Balar, Arjun Vasant...
European Urology. 85 (2024) 3 - p. 229-238 , 2024

Link: https://doi.org/10.1016/..

4

Blood tumor mutational burden and response to pembrolizumab..:

Bar, Jair ; Esteban, Emilio ; Rodríguez-Abreu, Delvys...
Lung Cancer. 190 (2024) - p. 107506 , 2024

Link: https://doi.org/10.1016/..

5

Baseline Mutations and ctDNA Dynamics as Prognostic and Pre..:

Pascual, Javier ; Gil-Gil, Miguel ; Proszek, Paula...
Clinical Cancer Research. 29 (2023) 20 - p. 4166-4177 , 2023

Link: https://doi.org/10.1158/..

6

Patient-Reported Health-Related Quality of Life in KEYNOTE-..:

Kim, Hye Ryun ; Awad, Mark M. ; Navarro, Alejandro...
JTO Clinical and Research Reports. 4 (2023) 11 - p. 100572 , 2023

Link: https://doi.org/10.1016/..

7

Fruquintinib versus placebo in patients with refractory met..:

Dasari, Arvind ; Lonardi, Sara ; Garcia-Carbonero, Rocio...
The Lancet. 402 (2023) 10395 - p. 41-53 , 2023

Link: https://doi.org/10.1016/..

8

Overall survival with palbociclib plus endocrine therapy ve..:

Martín, Miguel ; Zielinski, Christoph ; Ruiz-Borrego, Manuel...
European Journal of Cancer. 168 (2022) - p. 12-24 , 2022

Link: https://doi.org/10.1016/..

9

Trilaciclib prior to chemotherapy reduces the usage of supp..:

Ferrarotto, Renata ; Anderson, Ian ; Medgyasszay, Balazs...
Cancer Medicine. 10 (2021) 17 - p. 5748-5756 , 2021

Link: https://doi.org/10.1002/..

10

Analysis by region of outcomes for patients with advanced r..:

Schmidinger, Manuela ; Motzer, Robert J. ; Rolland, Frederic...
Acta Oncologica. 61 (2021) 1 - p. 52-57 , 2021

Link: https://doi.org/10.1080/..

11

Health-related quality of life with palbociclib plus endocr..:

Kahan, Zsuzsanna ; Gil-Gil, Miguel ; Ruiz-Borrego, Manuel...
European Journal of Cancer. 156 (2021) - p. 70-82 , 2021

Link: https://doi.org/10.1016/..

12

Adjuvant atezolizumab after adjuvant chemotherapy in resect..:

Felip, Enriqueta ; Altorki, Nasser ; Zhou, Caicun...
The Lancet. 398 (2021) 10308 - p. 1344-1357 , 2021

Link: https://doi.org/10.1016/..

13

Exploratory composite endpoint demonstrates benefit of tril..:

Dómine Gómez, Manuel ; Csőszi, Tibor ; Jaal, Jana...
International Journal of Cancer. 149 (2021) 7 - p. 1463-1472 , 2021

Link: https://doi.org/10.1002/..

14

Pathologic Complete Response Rates After Neoadjuvant Pertuz..:

Boér, Katalin ; Kahán, Zsuzsanna ; Landherr, László...
Pathology and Oncology Research. 27 (2021) - p. , 2021

Link: https://doi.org/10.3389/..

15

Randomized Phase II Study of Paclitaxel plus Alisertib vers..:

Owonikoko, Taofeek K. ; Niu, Huifeng ; Nackaerts, Kristiaan...
Journal of Thoracic Oncology. 15 (2020) 2 - p. 274-287 , 2020

Link: https://doi.org/10.1016/..